But with the end of the 14 year "patent protection period" of Pfizer's "Viagra" in China, it has reignited the desire of the domestic pharmaceutical industry to take a share in the anti ED drug market. There are many pharmaceutical companies that have submitted applications for the production of Viagra generic drugs, but Guangzhou Baiyunshan Pharmaceutical was the only one that ultimately obtained the first wholesale license for the production of Viagra generic drugs from the National Drug Administration.
Following the wave of licensing applications, Baiyunshan Pharmaceutical launched Baiyunshan Ginkgo, a generic drug of Viagra in the United States, the first domestically produced Viagra in the same year. As the main western medicine for treating ED, the global market is basically divided into three parts by Pfizer's "Blue" Viagra, Lilly's "Yellow" Xieli and Bayer's "tangerine" Arida. With the launch of domestically produced Viagra in 2014, Baiyunshan Jinge broke the monopoly of foreign pharmaceutical companies on male sexual dysfunction medication in China with an advantage of less than half the price of imported drugs.
According to the survey, 46% of men over 40 years old in China suffer from male erectile dysfunction. Most of the men with ED are young adults, especially in the IT industry and offices. These men usually focus on mental labor and lack adequate physical exercise. In addition, people with diabetes, hypertension, dyslipidemia, smoking and obesity are more likely to suffer from ED than the general population.
Male doctors remind that once impotence occurs and impotence persists, it is best to seek medical attention at the hospital to avoid excessive psychological burden over time. If the patient does not want surgical treatment, they can choose medication treatment and can take Baiyunshan Ginkgo - Erectile dysfunction medication treatment, preferably under the guidance of a doctor.